Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy

Kentaro Miyake; Tasuku Kiyuna; Masuyo Miyake; Kei Kawaguchi; Sang Nam Yoon; Zhiying Zhang; Kentaro Igarashi; Sahar Razmjooei; Sintawat Wangsiricharoen; Takashi Murakami; Yunfeng Li; Scott D. Nelson; Tara A. Russell; Arun S. Singh; Yukihiko Hiroshima; Masashi Momiyama; Ryusei Matsuyama; Takashi Chishima; Shree Ram Singh; Itaru Endo; Fritz C. Eilber; Robert M. Hoffman

doi:10.1038/s41392-018-0016-7

Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy

Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Kei Kawaguchi, Sang Nam Yoon, Zhiying Zhang, Kentaro Igarashi, Sahar Razmjooei, Sintawat Wangsiricharoen, Takashi Murakami, Yunfeng Li, Scott D. Nelson, Tara A. Russell, Arun S. Singh, Yukihiko Hiroshima, Masashi Momiyama, Ryusei Matsuyama, Takashi Chishima, Shree Ram Singh, Itaru EndoFritz C. Eilber, Robert M. Hoffman

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S. typhimurium A1-R with first-line chemotherapy using the CUP PDOX model. The present study is the first to use a CUP PDOX model, which was able to precisely distinguish the chemotherapeutic course. We found that a carboplatinum (CAR)-based regimen was effective for this CUP patient. We also demonstrated that S. typhimurium A1-R was more effective against the CUP tumor than first-line chemotherapy. Our results indicate that S. typhimurium A1-R has clinical potential for CUP, a resistant disease that requires effective therapy.

Original language	English
Article number	12
Journal	Signal Transduction and Targeted Therapy
Volume	3
Issue number	1
DOIs	https://doi.org/10.1038/s41392-018-0016-7
Publication status	Published - 2018 Dec 1
Externally published	Yes

ASJC Scopus subject areas

Genetics
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41392-018-0016-7

Cite this

Miyake, K., Kiyuna, T., Miyake, M., Kawaguchi, K., Yoon, S. N., Zhang, Z., Igarashi, K., Razmjooei, S., Wangsiricharoen, S., Murakami, T., Li, Y., Nelson, S. D., Russell, T. A., Singh, A. S., Hiroshima, Y., Momiyama, M., Matsuyama, R., Chishima, T., Singh, S. R., ... Hoffman, R. M. (2018). Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. Signal Transduction and Targeted Therapy, 3(1), [12]. https://doi.org/10.1038/s41392-018-0016-7

Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy. / Miyake, Kentaro; Kiyuna, Tasuku; Miyake, Masuyo et al.

In: Signal Transduction and Targeted Therapy, Vol. 3, No. 1, 12, 01.12.2018.

Research output: Contribution to journal › Article › peer-review

Miyake, K, Kiyuna, T, Miyake, M, Kawaguchi, K, Yoon, SN, Zhang, Z, Igarashi, K, Razmjooei, S, Wangsiricharoen, S, Murakami, T, Li, Y, Nelson, SD, Russell, TA, Singh, AS, Hiroshima, Y, Momiyama, M, Matsuyama, R, Chishima, T, Singh, SR, Endo, I, Eilber, FC & Hoffman, RM 2018, 'Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy', Signal Transduction and Targeted Therapy, vol. 3, no. 1, 12. https://doi.org/10.1038/s41392-018-0016-7

@article{ff96d31d3f8f4b41b944186a81ef7b9d,

title = "Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy",

abstract = "Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S. typhimurium A1-R with first-line chemotherapy using the CUP PDOX model. The present study is the first to use a CUP PDOX model, which was able to precisely distinguish the chemotherapeutic course. We found that a carboplatinum (CAR)-based regimen was effective for this CUP patient. We also demonstrated that S. typhimurium A1-R was more effective against the CUP tumor than first-line chemotherapy. Our results indicate that S. typhimurium A1-R has clinical potential for CUP, a resistant disease that requires effective therapy.",

author = "Kentaro Miyake and Tasuku Kiyuna and Masuyo Miyake and Kei Kawaguchi and Yoon, {Sang Nam} and Zhiying Zhang and Kentaro Igarashi and Sahar Razmjooei and Sintawat Wangsiricharoen and Takashi Murakami and Yunfeng Li and Nelson, {Scott D.} and Russell, {Tara A.} and Singh, {Arun S.} and Yukihiko Hiroshima and Masashi Momiyama and Ryusei Matsuyama and Takashi Chishima and Singh, {Shree Ram} and Itaru Endo and Eilber, {Fritz C.} and Hoffman, {Robert M.}",

note = "Publisher Copyright: {\textcopyright} 2018, The Author(s).",

year = "2018",

month = dec,

day = "1",

doi = "10.1038/s41392-018-0016-7",

language = "English",

volume = "3",

journal = "Signal Transduction and Targeted Therapy",

issn = "2095-9907",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy

AU - Miyake, Kentaro

AU - Kiyuna, Tasuku

AU - Miyake, Masuyo

AU - Kawaguchi, Kei

AU - Yoon, Sang Nam

AU - Zhang, Zhiying

AU - Igarashi, Kentaro

AU - Razmjooei, Sahar

AU - Wangsiricharoen, Sintawat

AU - Murakami, Takashi

AU - Li, Yunfeng

AU - Nelson, Scott D.

AU - Russell, Tara A.

AU - Singh, Arun S.

AU - Hiroshima, Yukihiko

AU - Momiyama, Masashi

AU - Matsuyama, Ryusei

AU - Chishima, Takashi

AU - Singh, Shree Ram

AU - Endo, Itaru

AU - Eilber, Fritz C.

AU - Hoffman, Robert M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S. typhimurium A1-R with first-line chemotherapy using the CUP PDOX model. The present study is the first to use a CUP PDOX model, which was able to precisely distinguish the chemotherapeutic course. We found that a carboplatinum (CAR)-based regimen was effective for this CUP patient. We also demonstrated that S. typhimurium A1-R was more effective against the CUP tumor than first-line chemotherapy. Our results indicate that S. typhimurium A1-R has clinical potential for CUP, a resistant disease that requires effective therapy.

AB - Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of S. typhimurium A1-R with first-line chemotherapy using the CUP PDOX model. The present study is the first to use a CUP PDOX model, which was able to precisely distinguish the chemotherapeutic course. We found that a carboplatinum (CAR)-based regimen was effective for this CUP patient. We also demonstrated that S. typhimurium A1-R was more effective against the CUP tumor than first-line chemotherapy. Our results indicate that S. typhimurium A1-R has clinical potential for CUP, a resistant disease that requires effective therapy.

UR - http://www.scopus.com/inward/record.url?scp=85053763023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053763023&partnerID=8YFLogxK

U2 - 10.1038/s41392-018-0016-7

DO - 10.1038/s41392-018-0016-7

M3 - Article

C2 - 29713497

AN - SCOPUS:85053763023

SN - 2095-9907

VL - 3

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

IS - 1

M1 - 12

ER -

Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting S. typhimurium A1-R is superior to first-line chemotherapy

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this